ClinicalTrials.gg
RecruitingNCT06891417Updated Nov 2, 2026

Phase 1 Study of Chlamydia Trachomatis mRNA Vaccine in Adults.

A Phase 1 interventional study of Chlamydia mRNA Vaccine and Placebo in Chlamydia Trachomatis Immunization, sponsored by Sanofi. Recruiting at 7 sites in Australia. Open to participants aged 18 Years to 44 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Sanofi · Phase 1, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.
Updated Nov 2, 2026Primary completion movedStudy completion moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 44 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety of two doses (Dose 1 and Dose 2) of Chlamydia mRNA Vaccine candidate in adult participants aged 18 to 29 years (Chlamydia trachomatis seronegative) or 18 to 44 years (Chlamydia trachomatis seropositive). There will also be an assessment to potentially obtain an early immunogenicity signal of the Chlamydia mRNA vaccine candidate.

This study will consist of 2 Cohorts assessing the safety of the two different doses: Cohort A (Dose 1 or placebo) and Cohort B (Dose 2 or placebo).

All participants will be followed up to 12 months after the last study intervention administration. Thus, the expected duration of the participant's involvement will be 18 months.

02

Conditions studied

  • Chlamydia Trachomatis Immunization

Browse trials for

Keywords

  • Chlamydia
03

In context

Chlamydia Infections

134 studies on the registry are indexed under Chlamydia Infections; 23 are open to participants now.

This study's planned enrollment of 80 is below the median of 600 across 94 interventional studies indexed under Chlamydia Infections.

Browse Chlamydia Infections studies →

Lead sponsor

Sanofi is the lead sponsor of 1,560 studies on the registry; 91 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Nov 2, 2026. See what changed

Ages eligible
18 Years to 44 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 to 29 years (Chlamydia trachomatis seronegative) or 18 to 44 years (Chlamydia trachomatis seropositive) on the day of inclusion
  • A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies:

    • Is of non-. To be considered of non-childbearing potential, a female must be surgically sterile.

OR

  • Is of childbearing potential and agrees to use an effective method from at least 4 weeks prior to study intervention administration until at least 4 weeks after the last study intervention administration.
  • A female participant of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation) at the screening visit and before each subsequent study intervention administration.

Exclusion criteria

Exclusion Criteria:

  • Any screening laboratory parameter with laboratory abnormalities as per local reference range and that are greater than Grade 2 or deemed in the opinion of the Investigator.
  • Participants who are Chlamydia trachomatis (CT) and/or Neisseria gonorrhea (NG) NAAT positive at screening visit
  • Self-reported or documented seropositivity for antigen and/or antibodies (Abs), virus surface antigen (HBsAg), hepatitis B core antibodies (HBcAbs), or virus (HCV) Abs infection at screening visit.
  • Known or suspected congenital or acquired immunodeficiency; or receipt of therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).
  • Known systemic to any of the study intervention components, or history of a life-threatening reaction to the study intervention(s) used in the study or to a product containing any of the same substances.
  • Previous history of myocarditis, pericarditis, and/or myopericarditis
  • Known history of previous history of Guillain-Barre syndrome and other immune mediated demyelinating conditions that include but are not limited to Multiple Sclerosis (MS), Neuromyelitis Optica (NMO), acute disseminated encephalomyelitis (ADEM), Transverse myelitis.
  • Screening (ECG) value that is consistent with possible myocarditis, pericarditis, and/or myopericarditis or screening ECG that demonstrates clinically relevant abnormalities, per investigator, that may affect participant safety or study results.
  • Self-reported thrombocytopenia, contraindicating intramuscular injection, based on investigator's judgment.
  • Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular injection, based on investigator's judgment.
  • Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion.
  • Moderate or severe acute febrile illness (temperature ≥ 38.0°C [≥ 100.4°F]) on the day of study intervention administration. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.
  • Alcohol, prescription drug, or substance abuse that, in the opinion of the Investigator, might interfere with the study conduct or completion.
  • Receipt of any mRNA vaccine/product in the 2 months preceding study enrollment or planned receipt of any mRNA vaccine/product within the 2 months following any study intervention administration.
  • Receipt of any vaccine (other than the study vaccine) in the 4 weeks preceding any study intervention administration or planned receipt of any vaccine (other than the study vaccine) in the 4 weeks following any study intervention administration, except influenza which may be received at least 2 weeks before or 2 weeks after any study vaccination.
  • Receipt of immune globulins, blood, or blood-derived products in the past 3 months.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Cohort A Group 1: Chlamydia trachomatis Seronegative

    Participants will receive three dose 1 injections of Chlamydia mRNA Vaccine

    Biological: Chlamydia mRNA Vaccine

  • Experimental
    Cohort B Group 2: Chlamydia trachomatis Seronegative

    Participants will receive three dose 2 injections of Chlamydia mRNA Vaccine

    Biological: Chlamydia mRNA Vaccine

  • Placebo comparator
    Cohort A and B Group 3: Chlamydia trachomatis Seronegative

    Participants will receive three injections of Placebo

    Other: Placebo

  • Experimental
    Cohort A Group 4: Chlamydia trachomatis Seropositive

    Participants will receive three dose 1 injections of Chlamydia mRNA Vaccine

    Biological: Chlamydia mRNA Vaccine

  • Experimental
    Cohort B Group 5: Chlamydia trachomatis Seropositive

    Participants will receive three dose 2 injections of Chlamydia mRNA Vaccine

    Biological: Chlamydia mRNA Vaccine

  • Placebo comparator
    Cohort A and B Group 6: Chlamydia trachomatis Seropositive

    Participants will receive three injections of Placebo

    Other: Placebo

Interventions

  • BiologicalChlamydia mRNA Vaccine

    Pharmaceutical Form: Suspension for injection Route of Administration: Intramuscular injection

  • OtherPlacebo

    Pharmaceutical Form: Solution for injection Route of Administration: Intramuscular injection

06

What researchers measure

Primary outcomes

  1. Presence of immediate unsolicited systemic adverse events (AEs)

    Number of participants with immediate unsolicited systemic adverse events (AEs) reported in the 30 minutes after each vaccine injection.

    Time frame: Within 30 minutes after each vaccine injection

  2. Presence of solicited injection site and systemic reactions

    Number of participants with solicited injection site and systemic reactions occurring up to 8 days after each vaccine injection.

    Time frame: Up to 8 days, including the day of each vaccine injection

  3. Presence of unsolicited AEs

    Participants with unsolicited AEs reported up to 28 days after each vaccine injection.

    Time frame: Up to 28 days after each vaccine injection.

  4. Presence of medically attended adverse events (MAAEs)

    Number of participants with MAAEs reported after each vaccine injection and up to 6 months after last vaccine injection.

    Time frame: Up to 6 months after last vaccine injection

  5. Presence of all serious AEs (SAEs) and all adverse events of special interest (AESIs)

    Number of participants with SAEs and all AESIs reported after each vaccine injection and up to 12 months after last vaccine injection

    Time frame: Up to 12 months after last vaccine injections

  6. Presence of related SAEs, and fatal SAEs

    Number of participants with related SAEs, and fatal SAEs throughout the study

    Time frame: Throughout the study, appriximatley 18 months

  7. Presence of out-of-range biological test results (Sentinel Cohort and Safety Subset of Main Cohort)

    Number of participants with out-of-range biological test results up to 8 days after each vaccine injection

    Time frame: Up to 8 days, including the day of each vaccine injection

07

Study locations

7 of 7 sites recruiting
  • Investigational Site Number : 0360002
    Bruce, Australian Capital Territory 2617, Australia
    Recruiting
  • Investigational Site Number : 0360006
    Maroubra, New South Wales 2035, Australia
    Recruiting
  • Investigational Site Number : 0360005
    Sydney, New South Wales 2010, Australia
    Recruiting
  • Investigational Site Number : 0360001
    Albion, Queensland 4010, Australia
    Recruiting
  • Investigational Site Number : 0360004
    Morayfield, Queensland 4506, Australia
    Recruiting
  • Investigational Site Number : 0360003
    Southport, Queensland 4222, Australia
    Recruiting
  • Investigational Site Number : 0360010
    Melbourne, Victoria 3000, Australia
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Mar 2025 (actual). Primary completion is estimated for Nov 2027, 31 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Jan 2028 → Nov 2027 and completion Jan 2028 → Nov 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2025
First posted
Mar 24, 2025
StartActual
Mar 27, 2025
Primary completionEst.
Nov 3, 2027was Jan 2028
CompletionEst.
Nov 3, 2027was Jan 2028
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jan 3, 2028→Nov 3, 2027
Nov 2, 2026
Study completion
Jan 3, 2028→Nov 3, 2027
Nov 2, 2026
Enrollment
1560→80
Nov 2, 2026
Eligibility
Maximum age 29 Years→44 Years; 1 inclusion criterion edited, 1 removed; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedAged 18 to 29 years (Chlamydia trachomatis seronegative) or 18 to 44 years (Chlamydia trachomatis seropositive) on the day of inclusion
  • RemovedNew sex partner within the past 6 months, or more than one current sex partner, or partner with known previous or coexisting sexually transmitted infection (STI), or inconsistent condom use
Exclusion criteria
  • EditedNote: The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Nov 2, 2026
Interventions
Arm changed Sentinel Cohort A Group 1: Chlamydia trachomatis Seronegative→Cohort A Group 1: Chlamydia trachomatis Seronegative; Sentinel Cohort B Group 2: Chlamydia trachomatis Seronegative→Cohort B Group 2: Chlamydia trachomatis Seronegative; Sentinel Cohort C Group 3: Chlamydia trachomatis Seronegative→Cohort A and B Group 3: Chlamydia trachomatis Seronegative; Sentinel Cohort A, B and C Group 4: Chlamydia trachomatis Seronegative→Cohort A Group 4: Chlamydia trachomatis Seropositive; Sentinel Cohort A Group 5: Chlamydia trachomatis Seropositive→Cohort B Group 5: Chlamydia trachomatis Seropositive; Sentinel Cohort B Group 6: Chlamydia trachomatis Seropositive→Cohort A and B Group 6: Chlamydia trachomatis Seropositive. Arms removed: Sentinel Cohort C Group 7: Chlamydia trachomatis Seropositive·Sentinel Cohort A, B and C Group 8: Chlamydia trachomatis Seropositive·Main Cohort Group 9: Chlamydia trachomatis Seronegative·Main Cohort Group 10: Chlamydia trachomatis Seronegative·Main Cohort Group 11: Chlamydia trachomatis Seronegative·and 5 more
All 10

Sentinel Cohort C Group 7: Chlamydia trachomatis Seropositive · Sentinel Cohort A, B and C Group 8: Chlamydia trachomatis Seropositive · Main Cohort Group 9: Chlamydia trachomatis Seronegative · Main Cohort Group 10: Chlamydia trachomatis Seronegative · Main Cohort Group 11: Chlamydia trachomatis Seronegative · Main Cohort Group 12: Chlamydia trachomatis Seronegative · Main Cohort Group 13: Chlamydia trachomatis Seropositive · Main Cohort Group 14: Chlamydia trachomatis Seropositive · Main Cohort Group 15: Chlamydia trachomatis Seropositive · Main Cohort Group 16: Chlamydia trachomatis Seropositive

Nov 2, 2026
Primary outcomes
2 time frame changed, 2 description edited
What changed in the outcomes
  • Time framePresence of solicited injection site and systemic reactionsUp to 7 days after each vaccine injection → Up to 8 days, including the day of each vaccine injection
  • Time framePresence of out-of-range biological test results (Sentinel Cohort and Safety Subset of Main Cohort)Up to 7 days after each vaccination injections → Up to 8 days, including the day of each vaccine injection
  • DescriptionPresence of out-of-range biological test results (Sentinel Cohort and Safety Subset of Main Cohort): how it is measured was reworded
  • DescriptionPresence of solicited injection site and systemic reactions: how it is measured was reworded
Nov 2, 2026
Secondary outcomes
2 removed
What changed in the outcomes
  • RemovedAssessment of serum binding antibodies to specific Chlamydia trachomatis antigens and whole bacteria in immunogenicity subsetTime frame: Before each vaccine injection through 1 month after each vaccine injection
  • RemovedGeometric mean cell-mediated immune response of antigen-specific T helper type 1 (Th1) and T helper type 2 (Th2) cytokine-producing T cells by phenotypeTime frame: Before each vaccine injection through 1 month after each vaccine injection
Nov 2, 2026
Title
Phase 1/2 Study of Chlamydia Trachomatis mRNA Vaccine in Adults Aged 18 to 29 Years.
Nov 2, 2026
Design
Removed Phase 2
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Primary completion Jan 3, 2028→Nov 3, 2027
    Study completion Jan 3, 2028→Nov 3, 2027
    Enrollment 1560→80
    Eligibility Maximum age 29 Years→44 Years; 1 inclusion criterion edited, 1 removed; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedAged 18 to 29 years (Chlamydia trachomatis seronegative) or 18 to 44 years (Chlamydia trachomatis seropositive) on the day of inclusion
    • RemovedNew sex partner within the past 6 months, or more than one current sex partner, or partner with known previous or coexisting sexually transmitted infection (STI), or inconsistent condom use
    Exclusion criteria
    • EditedNote: The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
    Primary outcomes 2 time frame changed, 2 description edited
    What changed in the outcomes
    • Time framePresence of solicited injection site and systemic reactionsUp to 7 days after each vaccine injection → Up to 8 days, including the day of each vaccine injection
    • Time framePresence of out-of-range biological test results (Sentinel Cohort and Safety Subset of Main Cohort)Up to 7 days after each vaccination injections → Up to 8 days, including the day of each vaccine injection
    • DescriptionPresence of out-of-range biological test results (Sentinel Cohort and Safety Subset of Main Cohort): how it is measured was reworded
    • DescriptionPresence of solicited injection site and systemic reactions: how it is measured was reworded
    Secondary outcomes 2 removed
    What changed in the outcomes
    • RemovedAssessment of serum binding antibodies to specific Chlamydia trachomatis antigens and whole bacteria in immunogenicity subsetTime frame: Before each vaccine injection through 1 month after each vaccine injection
    • RemovedGeometric mean cell-mediated immune response of antigen-specific T helper type 1 (Th1) and T helper type 2 (Th2) cytokine-producing T cells by phenotypeTime frame: Before each vaccine injection through 1 month after each vaccine injection
    Interventions Arm changed Sentinel Cohort A Group 1: Chlamydia trachomatis Seronegative→Cohort A Group 1: Chlamydia trachomatis Seronegative; Sentinel Cohort B Group 2: Chlamydia trachomatis Seronegative→Cohort B Group 2: Chlamydia trachomatis Seronegative; Sentinel Cohort C Group 3: Chlamydia trachomatis Seronegative→Cohort A and B Group 3: Chlamydia trachomatis Seronegative; Sentinel Cohort A, B and C Group 4: Chlamydia trachomatis Seronegative→Cohort A Group 4: Chlamydia trachomatis Seropositive; Sentinel Cohort A Group 5: Chlamydia trachomatis Seropositive→Cohort B Group 5: Chlamydia trachomatis Seropositive; Sentinel Cohort B Group 6: Chlamydia trachomatis Seropositive→Cohort A and B Group 6: Chlamydia trachomatis Seropositive. Arms removed: Sentinel Cohort C Group 7: Chlamydia trachomatis Seropositive·Sentinel Cohort A, B and C Group 8: Chlamydia trachomatis Seropositive·Main Cohort Group 9: Chlamydia trachomatis Seronegative·Main Cohort Group 10: Chlamydia trachomatis Seronegative·Main Cohort Group 11: Chlamydia trachomatis Seronegative·and 5 more
    All 10

    Sentinel Cohort C Group 7: Chlamydia trachomatis Seropositive · Sentinel Cohort A, B and C Group 8: Chlamydia trachomatis Seropositive · Main Cohort Group 9: Chlamydia trachomatis Seronegative · Main Cohort Group 10: Chlamydia trachomatis Seronegative · Main Cohort Group 11: Chlamydia trachomatis Seronegative · Main Cohort Group 12: Chlamydia trachomatis Seronegative · Main Cohort Group 13: Chlamydia trachomatis Seropositive · Main Cohort Group 14: Chlamydia trachomatis Seropositive · Main Cohort Group 15: Chlamydia trachomatis Seropositive · Main Cohort Group 16: Chlamydia trachomatis Seropositive

    Design Removed Phase 2
    Title Phase 1/2 Study of Chlamydia Trachomatis mRNA Vaccine in Adults Aged 18 to 29 Years.
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06891417
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Mar 24, 2025
Start date
Mar 27, 2025
Primary completion
Nov 3, 2027 (estimated)
Completion
Nov 3, 2027 (estimated)
Last update
Nov 2, 2026

Study contacts

Trial Transparency email recommended (Toll free for US & Canada)
Contact
Contact-US@sanofi.com
800-633-1610 ext. option 6

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion